Ras Al Khaimah, United Arab Emirates, 23rd  August, 2015 

Julphar announced sales revenue worth AED 799.5 million in the first half of this year, with a growth of 5% compared to the same period of 2014. The company's financial results, which were shared within the Board of Director's report, showed a total profit of AED 497.8 million, up 9% yoy.

Julphar reached a new milestone earlier this year for the recombinant Insulin Glargine. In collaboration with one of the leading biopharmaceutical R&D companies in Europe, it succeeded in developing a qualified and well-characterized cell line for the production of Glargine. This was followed by further process development and optimization at pilot scale.

Julphar also successfully concluded Phase I clinical trial of its Biosimilar Human Insulin, that demonstrated similarity of its investigational biosimilar human insulin compared to the EU-licensed reference product Eli Lilly HUMINSULIN® and has become the first company in the Middle East to have clinical trial filing accepted under the EMA biosimilar guidelines.

Julphar produces crude insulin using crystals derived from recombinant DNA technology, a state of the art facility that consists of 11 plants at its headquarters in Ras Al Khaimah, as it produces 213 products in different dosage forms and therapeutic areas that are distributed in over 40 countries.

-Ends-

About Julphar
Julphar is one of the largest pharmaceutical manufacturers and distributors in the Middle East and North Africa (MENA) region.

With twelve state-of-the-art and ISO certified manufacturing facilities, Julphar currently holds 3,646 registration certificates for its products. The organization's mission is to offer high quality medicines at competitive prices, whilst working towards positioning Ras Al Khaimah as a robust and growing market with a diversified economic base.

Well positioned to meet tomorrow's healthcare challenges, Julphar maintains a diverse product portfolio which targets major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.

In line with its objective to promote better diabetes management in the region, Julphar is now the only company in the Middle East to produce the raw material needed to make insulin through its division dedicated to Diabetes.

Julphar employs approximately 3000 personnel around the world and the company reported year-end sales of approximately AED 1.44 billion in 2014.

© Press Release 2015